

## LUI FRANCIOSI, PhD

3119 Daybreak Avenue, Coquitlam, BC, V3C 2G5

Mob: +1-778-998-6260

Email: [l.franciosi@telus.net](mailto:l.franciosi@telus.net)

### **SKILLS PROFILE**

**EXECUTIVE & OPERATIONS MANAGEMENT:** I possess a range of skills related to executive and operations management of small and mid-sized companies in the private sector and the public markets. I have overseen basic & clinical sciences of various drug development programmes, financial management, investor relations, & general office administration. I have also gained experience in interviewing, hiring, and managing a team of employees, consultants & contractors to ensure that both laboratory and clinical trials are implemented on time and within budget to highest regulatory standards (GMP, GLP & GCP). I have experience in identifying competitors & their products/patents; promoting company products; identifying and gaining product licenses; and preparing for, and conducting, due diligence exercises on company assets. I have held a license from the Fraser Health Authority to direct a unionized long-term care facility on behalf of a large private multi-national company. I was also a residential care facility license holder with the Vancouver Coastal Health Authority.

**CLINICAL & GENERAL PHARMACOLOGY:** I have knowledge of standard and experimental drugs related to dementia, Chronic Obstructive Pulmonary Disease (COPD), asthma, allergic rhinitis, clinical anaesthesia, acute/chronic pain – inflammation, chronic cough, and wound management. I am familiar with standard clinical trial designs and biostatistical methods. I have acquired skills related to various modelling and simulation techniques applied to clinical trial design such as Bayesian statistics (WinBugs), compartmental & non-compartmental analysis (Pharsight's WinNonLin) and Non-Linear Mixed Effect Modelling (NONMEM). I am acquainted with the various drug development phases and related regulatory guidelines and processes, i.e., FDA, EMEA & ICH Guidelines that address GCPs. I have gained *in vitro* & *in vivo* pharmacology skills by evaluating novel local anaesthetics for pain & arrhythmias as well as phosphodiesterase 3/4 inhibitors for COPD & asthma. Main animal species used were the mouse, rat, guinea pig, rabbit, dog, and primates. I am familiar with standard apparatus & recording devices used in the laboratory & operating room setting. I recently also obtained P.I.E.C.E.S. clinical training that deals with handling aggressive resident behaviour in long term care.

**RESEARCH INFORMATICS / CONTROL SYSTEMS:** I have investigated recurring problems in the clinical trial setting to determine if a computer expert system could improve the execution of clinical trials. I have interrogated trial design and statistics experts and gained have experience of trial workflow through participation in the implementation of academic and industrial trials. During this time, I have developed a knowledgebase and algorithm to advise investigators in the generation of a trial protocol. I have conducted several observational studies and then tested system effectiveness against the standard textbook method by performing a randomised controlled trial. I have assisted control engineers and anaesthetists in the evaluation of a computer-controlled drug delivery system in animals with varied receptor populations that mimic the extremes of disease population variance. From this, I have acquired some understanding of control systems theory, the relevant components & processes such as sensors, actuators, set-point selection, and the related industry products like Brainwave Controller Technology.

**MEDICAL DEVICE DEVELOPMENT:** I have skills related to development and clinical evaluation of a wound management system for small and large wounds. In particular, I have knowledge of wound care products and related pharmacology, including business plan development, Delphion/IBM patent searching, prototype development, International Standards Organization (ISO), testing and certification, clinical trials, venture capital searching, and some FDA regulatory (5-10-K requirement).

**PROJECT MANAGEMENT / DECISION MAKING:** I have a wide range of skills related to meeting management, development of a manual of standard operating procedures for clinical research, and knowledge of resource management, budgeting, planning, scheduling, team dynamics, and negotiation skills.

**GENERAL SKILLS:** These include critical review of the scientific literature; journal manuscript & company report writing; lecture/seminar preparation and university teaching. I can demonstrate proficiency in the use of a wide range of software including KRONOS Time Keeping, Point Click Care (PCC), JD Edwards - Accounts Payable, Microsoft Office Suite (Word, Excel, PowerPoint, Access, Visio, and Project) and SharePoint, Adobe Acrobat, Lotus Notes, Reference Manager, GraphPad & NCSS statistics programs, and BusinessObjects 5.1 database; and web page design & development skills. I have travelled extensively for work/pleasure around North & South America, Western & Eastern Europe, & South-East Asia.

## **EMPLOYMENT HISTORY**

### **FRANCIOSI CONSULTING LTD, LONDON, UK & VANCOUVER, CA**

**1998 – PRESENT**

- Independent clinical trials consultant, supporting companies and universities in Canada, United Kingdom, The Netherlands, Italy, and Malaysia
- 

### **UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, CA**

**Dept. of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine**

#### ***Adjunct Professor***

**2010 – PRESENT**

- Teaching responsibilities for PCTH 300, 305 and 402 courses and laboratories looking at basic and clinical pharmacology as well as methods of pharmacology; involves 1 to 3 hours of lecture and/or lab time, done once yearly for each course
  - Teaching responsibility for UBC's Vancouver Summer Program in Medicine that hosts circ. 50 international students with medical and pharmacy backgrounds; involves 3 lecture hours on clinical research design and implementation and 1-hour group assignment, done once yearly (every July)
- 

### **RENFREW CARE CENTRE, VANCOUVER, CA**

**Retirement Concepts / Well Being Senior Services Ltd. (Residential Care)**

#### ***General Manager***

**April 2019 – June 2019**

- Managed a Vancouver Coastal Health (VCH) licensed residential care facility that belongs to a private BC company
    - o Responsible for 150 unionized staff, 10 non-unionized registered nurses and 106 complex care residents with an average yearly operational budget of CAD \$7.5 million
    - o Managed a Medical Coordinator & six (6) department managers, i.e., Nursing Care, Support Services (i.e., Food, Dietary & Housekeeping), Recreation, Maintenance, Finance, & Human Resources
  - Maintained 100% occupancy for all 106 VCH funded beds
  - Negotiated collective agreement with one union: BCGEU (April - May 2019)
  - Complied with all relevant Provincial and Federal acts and regulations: health long-term care, labour relations, WorkSafeBC, and medical/nursing standards
- 

### **VERITAS PHARMA INC., VANCOUVER, CA**

#### ***Chief Executive Officer***

**DECEMBER 2015 – FEBRUARY 2019**

- Responsible for a publicly traded pharmaceutical company in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP
  - Helped raise \$2 million CAD for its subsidiary company (research arm), Cannevert Therapeutics Ltd. (CTL), which is advancing the science behind medical cannabis
  - Aimed to grow and develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical cannabis claims
  - Used a low-cost research and development model to help drive shareholder value, and speed-to-market
  - Oversaw a strong management team made up of veteran academic pharmacologists, anaesthesiologists & chemists
  - Mandate was to patent protect CTL's intellectual property (cultivars & strains), sell or license to medical clinics, insurance industry and pharma; and target multi-billion dollar global markets
- 

### **ROYAL CITY MANOR, NEW WESTMINSTER, CA**

**Revera Inc. (Long Term Care Division)**

#### ***Executive Director***

**JULY 2013 – MARCH 2017**

- Directed a Fraser Health licensed long-term care facility that belongs to a private multi-national, in particular, managing 220 unionized staff and caring for 165 complex care residents with an average yearly revenue of CAD \$10 million
    - o Managed a Medical Director & eight (8) department managers, i.e., Nursing Care, Food Services, Dietary, Recreation & Volunteer Services, Environmental Services, Finance, Human Resources, & Marketing
    - o Implemented the following long-term care programmes for 2014-2015:
      - person-centred care and poly-pharmacy research with Medical Director and the Director of Care
      - a leisure & well-being model with Recreation Manager
-

- pleasurable dining with Food Services and Dietary Managers
- Worked with three funding sources/agencies – Fraser Health Authority, Vancouver Coastal Health and Private Pay
- Negotiated & implemented collective agreements with two unions: BC Nurses Union (Oct. 2013) and Hospitals Employees Union (June 2014)
- Complied with all relevant Provincial and Federal acts and regulations: health long-term care, labour relations, workers compensation board, and medical/nursing standards
- Obtained Accreditation Canada Award (Nov. 2013) with Commendation (Mar. 2014)
- Attended regular meetings & conferences of the BC Patient Safety & Quality Council (bcpsqc.ca)

**VERONA PHARMA PLC, LONDON, UK & VANCOUVER, CA**

**Chief Operating Officer (COO)**

**2006 – June 2013**

- Oversaw the business & clinical operations of a publicly trading company on the AIM London Stock Exchange (LSE: VRP), in particular, managing 25+ employees and consultants along with 1-2 contract research organisations (CROs) at any given time with a monthly budget of GBP £100,000 (CAD \$150,000)
  - o Managed three drug development programmes
    - Planned and implemented GLP and GCP studies of a new drug (RPL554) and novel anti-inflammatory polysaccharides (NAIPS) technology for allergic rhinitis, asthma and Chronic Obstructive Pulmonary Disease (COPD)
    - Planned and implemented GCP trials of a new drug (VRP700) for chronic cough
    - Oversaw preclinical and clinical trials to GLP and GCP standards with the assistance of a variety of CROs; these included: Centre for Human Drug Research (CHDR) and ABL Laboratories in The Netherlands; CEREP in France; RCC Ltd. in Switzerland; Lab Research in Hungary & Canada; and Manchester's Medicines Evaluation Unit, Charles River Laboratories, Quintiles, PneumoLabs, Sequani, and Huntingdon Life Sciences in the UK
    - Oversaw the design, approval and conduct of seven (7) phase I/II clinical trials in United Kingdom, The Netherlands and Italy; this included establishment of clinical trial plans; timelines; budgets; protocol and CRF development; SOP development and refinement; submissions of clinical trial applications and INDs to EU, UK, Dutch and Italian national authorities and local ethics committees; day-to-day oversight; protocol amendments; study monitoring, auditing, and closeouts; study report writing; and related writing of research publications.
    - Overseen the manufacturer and formulation of all active product ingredients to GMP standards with the help of UK chemistry consultants and CROs such as Onyx Scientific – IPCA, Tocris Cookson MedPharm, and Moorfields Pharmaceuticals in the UK
  - o Oversaw business operations in London and Vancouver, in particular, legal aspects such as setting up CDAs, service agreements & contracts; dealing with finances such as budget setup and spending oversight; performing investor relations duties such as handling investors phone calls and emails; and dealing with office infrastructure such as general office duties, data storage and retrieval, communications, & computing
- Sought out competitors and their products/patents as well as promoted company products to obtain potential product licenses; and prepared for and conducted due diligence exercises on company assets
- Performed tasks related to the admissions of the company on to the London Stock Exchange as well as prepared and handled news releases (as per LSE rules).

**KING'S COLLEGE LONDON, UK**

Sackler Institute of Pulmonary Pharmacology

**Research Fellow**

**2006**

**GLAXOSMITHKLINE PLC, LONDON, UK**

**Post-Doctoral Fellow**

**2005 - 2006**

**LEIDEN UNIVERSITY, LEIDEN, NL**

Leiden Amsterdam Center of Drug Research (LACDR)

**Post-Doctoral Fellow**

**2003 – 2005**

**Course Lecturer**

**2004**

**UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, CA**

Depts. of Anesthesiology, Pharmacology &amp; Therapeutics, Faculty of Medicine

Dept. of Electrical &amp; Computer Engineering, Faculty of Applied Science

Dept. of Adult Education, Faculty of Education

**PhD Student****1998 – 2003****UNIVERSITY OF BRITISH COLUMBIA, Vancouver, CA**

Clinical Pharmacology Research Organization (CPRO)

**Clinical Trial Manager (P/T)****1999 – 2003****Clinical Research Associate (P/T)****1994 – 1996****Clinical Research Assistant (P/T)****1991 – 1994****NORTRAN PHARMACEUTICALS LTD (now CARDIOME PHARMA CORP), VANCOUVER, CA****Clinical Research Co-ordinator & Study Monitor****1997-1998****Clinical Research Associate (P/T)****1995-1996****Data Manager (P/T)****1999-2000****RHYTHM SEARCH DEVELOPMENTS (RSD) LTD, VANCOUVER, CA****Summer Industrial Research Assistant****1994****Summer Industrial Research Assistant****1993****AERO-THERAPEUTIC WOUND MANAGEMENT (ATM) LTD, VANCOUVER, CA****Clinical Coordinator****1994-1996****Product Development Researcher****1993****UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER, CA**

Depts. of Anesthesia and Pharmacology &amp; Therapeutics, Faculty of Medicine

**Course Lecturer****1996 - 1999****Research Assistant****1999****Research Assistant****1995 - 1997****Volunteer Research Assistant****1990 - 1992****EDUCATION****King's College London (UK)**

Research Fellow

**2006****GlaxoSmithKline (UK)**

Post-Doctoral Fellow

**2005 – 2006****Leiden University (NL)**

Post-Doctoral Fellow

**2003 – 2005****University of British Columbia (CA)**

PhD (Pharmacology &amp; Therapeutics)

**1998 – 2003****University of British Columbia (CA)**

MSc (Pharmacology &amp; Therapeutics)

**1994 – 1998****University of British Columbia (CA)**

BSc (Pharmacology &amp; Therapeutics)

**1989 – 1993****Notre Dame Secondary (CA)****1985-1989****AWARDS AND DISTINCTIONS:****University Graduate Fellowship** Faculty of Graduate Studies, UBC, \$8,000CAN.**1999 - 2000****Travel Award** Faculty of Graduate Studies, UBC, \$400CAN.**1999****University Graduate Fellowship** Faculty of Graduate Studies, UBC, \$13,500CAN.**1996 - 1997****Summer Studentship** Faculty of Medicine, UBC, \$3,500CAN.**1996****Dean's Honours List** Faculty of Science, UBC**1993**

## **CONTINUING EDUCATION / CERTIFICATES:**

<b>The Continuing Legal Education Society of British Columbia</b>	Corporate Governance 2017 (Credit Course)	<b>Oct. 2017</b>
<b>Simon Fraser University</b> Burnaby, BC, Canada	Public Companies: Financing, Governance and Compliance (PBCO200-VA11771 – Non-Credit Course)	<b>Sept. 2017</b>
<b>Fraser Health Residential Care</b> Burnaby, BC, Canada	P.I.E.C.E.S. Manager & 24 Hour Resource Person Education (1 Day & 3 Day Certificate Courses by Anita Wahl, respectively)	<b>Sept.-Nov.2014</b>
<b>Carr Quality Consultancy Ltd.</b> United Kingdom	Good Clinical Practice Re-certification – ICH GCP, EU Directives, UK Statutory Instruments, Annex XIII (Course)	<b>Mar. 2013</b>
<b>St. John Ambulance</b> Port Moody, BC, Canada	Standard First Aid with CRP- C - Automated External Defibrillator (3-year Certificate – No. 1-2KN4KU)	<b>2010 – 2013</b>
<b>St. John Ambulance</b> London, United Kingdom	Oxygen Administration (1-year Certificate – No. 0900129197)	<b>2009 – 2010</b>
<b>Cmed Adaptive Trial Design Forum</b> Old Windsor, UK	Adaptive Trial Design & Bayesian Statistics Course	<b>Mar. 2009</b>
<b>Carr Quality Consultancy Ltd.</b> United Kingdom	Good Clinical Practice – ICH GCP, EU Directives, UK Statutory Instruments, Annex XIII (Course)	<b>Feb. 2009</b>
<b>British Red Cross</b> London, United Kingdom	Automated External Defibrillator (AED) with Life Support (1-year Certificate – No. 1062-AEL))	<b>Jan. 2009</b>
<b>Warwick Business School,</b> University of Warwick Coventry, United Kingdom	Financial Accounting, Marketing Analysis, Modelling & Analysis for Management, Organisational Behaviour, & Operations Management (Part-Time Courses)	<b>2005 - 2006</b>
<b>PharmaED with GSK</b> Greenford, United Kingdom	Chronic Obstructive Pulmonary Disease (COPD) Workshop	<b>Feb. 2006</b>
<b>Dept. of Epidemiology &amp; Public Health,</b> Imperial College London, United Kingdom	Short Course on Bayesian Hierarchical Models (Certificate / GSK Training Session)	<b>Feb. 2005</b>
<b>Medical Research Council Biostatistics Unit,</b> Cambridge University, United Kingdom	Bayesian Approaches to Evaluation of Health Care Interventions Course (Certificate / GSK Training Session)	<b>Sept. 2004</b>
<b>Population Approach Group in Europe</b> - Uppsala, Sweden	10 <sup>th</sup> Annual Meeting on PK-PD Modelling Lectures	<b>June 2004</b>
<b>Population Approach Group in Europe</b> – Verona, Italy	9 <sup>th</sup> Annual Meeting on Pharmacokinetic-Pharmacodynamic Modelling Lectures	<b>June 2003</b>
<b>Therapeutics Initiative,</b> UBC, Vancouver, Canada	13 <sup>th</sup> Annual Drug Therapy Decision Making Course (Certificate)	<b>May 2002</b>
<b>Therapeutics Initiative,</b> UBC, Vancouver, Canada	11 <sup>th</sup> Annual Drug Therapy Decision Making Course (Certificate)	<b>May 2000</b>
<b>American College of Clinical Pharmacology,</b> Maryland, US	Pharmaceutical Education (Certificate:1.8 CEU or 18Hours)	<b>Sept. 1999</b>
<b>Drug Information Association</b> Taipei, Taiwan	Asian Clinical Trials and FDA & ICH Guidelines (Certificate)	<b>Oct. 1998</b>
<b>Clinical Trials Centre,</b> Univ. of Hong Kong, China	GCPs and Biostatistics Workshops (Certificate)	<b>Oct. 1998</b>
<b>BC Institute of Technology</b> Vancouver, Canada	GCPs and Project Management (Certificate)	<b>Mar. 1998</b>
<b>BC Consortium for Clinical Trials &amp; UBC,</b> Van., Canada	'Clinical Trials 2000' Course (Certificate)	<b>Oct. 1997</b>
<b>Canadian HIV Trials Network</b> Vancouver, Canada	GCPs & Adverse Event Management (Onsite Instruction)	<b>Apr.- Jun.,1996</b>
<b>Department of Health Care and Epidemiology,</b> UBC	The Design and Analysis of Clinical Trials (HCEP506)	<b>Jan.- Apr.,1996</b>
<b>Department of Pharmacology and Therapeutics,</b> UBC	Experimental Design and Bioassay (PCTH512)	<b>Jan.- Apr.,1996</b>
<b>BC Consortium for Clinical Trials &amp; UBC,</b> Van., Canada	'Clinical Trials 2000' Course (Certificate)	<b>Oct. 1995</b>
<b>BC Transplant Society</b> Vancouver, Canada	Good Clinical Practices (GCPs) Workshop (Certificate)	<b>Jan. 1995</b>

## **PROFESSIONAL MEMBERSHIPS**

Canadian College of Health Leaders (CCHL) – 2019 – present.  
American Medical Informatics Association (AMIA), 2001 – 2003.  
American Medical Writers Association (AMWA), 1998 – 2003.  
Association of Clinical Research Professionals (ACRP), 1998 – 2004.

British Pharmacological Society (BPS), 2004 – present.  
Clinical Research Professionals of British Columbia (CRPBC), 1998 – 2003.  
Drug Information Association (DIA), 1998 – 2010.  
European Respiratory Society (ERS), 2003 – present.  
IEEE Engineering in Medicine and Biology Society (EMBS), 2001 – present.  
International Society for System Sciences – Medical Systems SIG (ISSS), 1997 – 2003.  
Pharmacological Society of Canada (PSC), 2003-present.

## **REVIEWER**

European Respiratory Journal, 2004 – present.  
Pulmonary Pharmacology & Therapeutics, 2005 – present.  
Respiration, 2005 – present.  
Respiratory Medicine, 2006 – present.  
Respiratory Research, 2006 – present.

## **REFEREED PUBLICATIONS**

### **JOURNAL PAPERS:**

1. Lavorini F, Spina D, Walker MJ, **Franciosi L**, Page CP, Fontana GA. Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study. **Pulmonary Pharmacology & Therapeutics**. Oct; 40: 91-94, 2016.
2. **Franciosi LG**, Diamant Z, Banner K, Zuiker R, Morelli N, Kamerling I, De Kam M, Burggraaf J, Cohen AF, Cazzola M, Calzetta L, Singh D, Spina D, Walker M, Page CP. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. **The Lancet (Respiratory Medicine)** 1 (9): 714-727, 2013.
3. Cazzola M, MacNee W, Martinez FJ, Rabe KF, **Franciosi LG**, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravittles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. **European Respiratory Journal** 31 (2):416-69, 2008.
4. **Franciosi LG**, Page CP, Celli B, Cazzola, M, Walker MJA, Danhof M, Rabe KF, Della Pasqua OE. Markers of Exacerbation Severity in Chronic Obstructive Pulmonary Disease. **Respiratory Research** 10; 7:74, 2006.
5. **Franciosi LG**, Page CP, Celli B, Cazzola, M, Walker MJA, Danhof M, Rabe KF, Della Pasqua OE. Markers of Disease Severity in Chronic Obstructive Pulmonary Disease. **Pulmonary Pharmacology & Therapeutics** 19 (3):189-99, 2006.
6. Nguan C, **Franciosi LG**, Butterfield NN, MacLeod BA, Jens M, Fenster HN. A Prospective, Double-blind, Randomised Cross-over Study Evaluating Changes in Urinary pH for Relieving the Symptoms of Interstitial Cystitis. **British Journal of Urology International** 95 (1): 91-94, 2005.
7. Schwarz SKW, Butterfield NN, MacLeod BA, Kim EY, **Franciosi LG**, Ries CR. Under “Real World” Conditions, Desflurane Increases Drug Cost Without Speeding Discharge After Short Ambulatory Anesthesia Compared to Isoflurane. **Canadian Journal of Anesthesia** 51 (9): 892-898, 2004.
8. Butterfield NN, Ries CR, Schwarz SKW, **Franciosi LG**, MacLeod BA, Day B. Combined pre- and postsurgical bupivacaine wound infiltrations decrease postoperative opioid requirements after knee ligament reconstruction. **Canadian Journal of Anesthesia** 48 (3): 245-250, 2001.
9. Ries CR, Azmudéh A, **Franciosi LG**, Schwarz SKW, MacLeod BA. Cost comparison of sevoflurane with isoflurane anesthesia in arthroscopic meniscectomy surgery. **Canadian Journal of Anesthesia** 46 (11): 1008-1013, 1999.
10. Schwarz SKW, **Franciosi LG**, Ries CR, Regan WD, Davidson RG, Nevin K, Escobedo S, MacLeod BA. Addition of femoral 3-in-1 blockade to intra-articular ropivacaine 0.2% does not reduce analgesic requirements following arthroscopic knee surgery. **Canadian Journal of Anesthesia** 46 (8): 741-747, 1999.

### **CONFERENCE ABSTRACTS:**

1. **Franciosi LG**, Zuiker R, Kamerling IMC, Burggraaf J, Cohen AF, Walker M & Page CP. RPL554, a dual PDE3/4 inhibitor, is well tolerated and maintains bronchodilator activity when administered by inhalation to mild-to-moderate allergic asthmatics on 6 consecutive days. (Accepted Abstract – Poster). **American Thoracic Society Annual Meeting**, 17-22 May 2013, Philadelphia, PA, USA.
2. **Franciosi LG**, Diamant Z, Morelli N, Kam M, Cohen A, Walker M, & Page CP. A Combined Phase I/IIa Study of the Safety, Bronchodilator and Bronchoprotective Effects of Nebulized RPL554, a dual PDE3/4-inhibitor, in Healthy Subjects and Asthmatics. (Abstract – Oral). **ISAF-International Severe Asthma Forum**, 11-13 Oct. 2012, Gothenburg, Sweden.
3. **Franciosi LG**, Della Pasqua OE. Markers of Disease Severity in COPD Patients with Exacerbations (Abstract – Poster or Oral). **American Thoracic Society Annual Meeting**, 19-24 May 2006, San Diego, California, USA.

4. **Franciosi LG**, Yang SY, Della Pasqua OE. Assessment of the Probability of COPD Exacerbations Using Poisson Regression Models (Abstract Poster & Oral). **British Pharmacology Society Winter Meeting**, 20-22 December 2005, London, United Kingdom.
5. **Franciosi LG**, Page CP, Celli B, Cazzola, M, Walker MJA, Danhof M, Rabe KF, Della Pasqua OE: Markers of Exacerbation Severity in Chronic Obstructive Pulmonary Disease (Abstract – Poster). **European Respiratory Society Congress Annual Congress**, 17-21 September 2005, Copenhagen, Denmark.
6. **Franciosi LG**, Della Pasqua OE. Clinical Study Measures Not Sensitive to the Severity of Chronic Obstructive Pulmonary Disease (Abstract – Poster). **American Thoracic Society Annual Meeting**, 20-25 May 2005, San Diego, California, USA.
7. **Franciosi LG**, Page CP, Celli B, Cazzola, M, Walker MJA, Danhof M, Rabe KF, Della Pasqua OE. Which Markers other than FEV<sub>1</sub> Reflect Disease Progression in Chronic Obstructive Pulmonary Disease (Abstract – Poster & Oral). **European Respiratory Society Annual Congress**, 4-8 September 2004, Glasgow, Scotland.
8. **Franciosi LG**, Butterfield NN, MacLeod BA. Randomized Controlled Trial of a Clinical Trial Protocol Generating Module (Abstract – Poster). **MEDINFO2004 (Hosted by the International & American Medical Informatics Associations)**, 7-11 September 2004, San Francisco, California, USA.
9. **Franciosi LG**, Della Pasqua OE: Lack of Correlation Between Clinical Endpoints and COPD Disease Progression (Abstract – Poster). **World Congress of Clinical Pharmacology (Hosted by the American/ Society for Clinical Pharmacology and Therapeutics)**, 1-6 August 2004, Brisbane, Australia.
10. Nguan C, **Franciosi LG**, Butterfield NN, MacLeod BA, Jens M, Fenster HN. A Prospective, Double-blind, Randomised Cross-over Study Evaluating Changes in Urinary pH for Relieving the Symptoms of Interstitial Cystitis (Abstract – Poster & Oral). **American Urological Association Annual Meeting**, 8-13 May 2004, San Francisco, California, USA.
11. Butterfield NN, Kim EY, Schwarz SKW, Ries CR, **Franciosi LG**, MacLeod BA. Comparison of isoflurane and desflurane for short ambulatory anesthesia: Drug cost and recovery profiles. **Anesthesia & Analgesia**. 94(2S): S118, 2002.
12. **Franciosi LG**, Butterfield NN, MacLeod BA, Walker MJW, Sutter MC. Development and Evaluation of a Quality Assessment Instrument for Clinical Trial Protocols (Abstract - Poster). **XIVth World Congress of Pharmacology**, 7-12 July 2002, San Francisco, California, USA.
13. Butterfield B.B., MacLeod BA, Graf P., Zis AP, Eyre J, Nafde N, **Franciosi LG**, Walker MJA. Cognitive Recovery Following ECT: A Comparison Between Thiopentone and Propofol Anesthesia (Abstract - Poster). **XIVth World Congress of Pharmacology**, 7-12 July 2002, San Francisco, California, USA.
14. Gilhuly T, MacLeod BA, **Franciosi LG**, Butterfield BB, Chan S, Tabrizchi R. Evaluation of the Dose Response and Pharmacokinetics of Conopeptide G1 in the Rabbit Model (Abstract - Poster). **XIVth World Congress of Pharmacology**, 7-12 July 2002, San Francisco, California, USA.
15. **Franciosi LG**, Butterfield NN, MacLeod BA. Evaluating the Process of Generating a Clinical Trial Protocol. **Proceedings of the American Medical Informatics Association Annual Symposium**, p.1021, 2002.
16. **Franciosi LG**, MacLeod BA, Huzmezan MH, Ticea C, Cosma A. A Web-Based Clinical Trial Expert System; Human Information and Education Systems. **Proceedings of Systemics, Cybernetics and Informatics Society** 8: 242-247, 2001
17. **Franciosi LG**, MacLeod BA, Huzmezan MI, Ticea C, Cosma A, Rubenson K. Preliminary Evaluation of A Protocol Generating System. **Proceedings of the Western Pharmacology Society** 44: 212, 2001.
18. Ries CR, Butterfield NN, MacLeod BA, **Franciosi LG**. Breast Block for Breast Surgery (Abstract - Poster). **12th World Congress of Anaesthesiologists**, 4<sup>th</sup> June 2000, Montreal, QB, Canada.
19. Lang CC, Murugasu J, Lee TC, **Franciosi LG**, Doci A, Ali AB: Clinical evaluation of RSD921 as a local anaesthetic in patients undergoing venous cannulation for elective treatment. **Clinical Pharmacology & Therapeutics** 67 (2): PIII-1, 142, Feb. 2000.
20. **Franciosi LG**, Murugasu J, Ali SB, Doci A, Lee, TC, and Lang CC. Phase II Clinical Trial of RSD921 as a Local Anaesthetic in Patients Undergoing Venous Cannulation for Elective Treatment. **Journal of Clinical Pharmacology** 39 (9): A32, 977, Sept. 1999.
21. Doci A, Murugasu J, Ali SB, **Franciosi LG**, Lee TC, Lang CC: Local anesthetic effects of intradermal RSD921 in healthy subjects. **Clinical Pharmacology & Therapeutics** 65 (2): PIII-2, 177, Feb. 1999
22. Schwarz SKW, MacLeod BA, Ries CR, **Franciosi LG**, Regan WD, Davidson RG, Nevin K, Escobedo S: Femoral 3-in-1 block for post-operative pain control in arthroscopic cruciate ligament repair. **Canadian Journal of Anesthesia** 45 PII: A37, 1998.
23. MacLeod BA, Azmudéh A, **Franciosi LG**, Ries CR, Schwarz SKW: Evaluation of the cost of sevoflurane compared to isoflurane anesthesia. **Canadian Journal of Anesthesia** 45 PII: A26, 1998.
24. Polyakov GM, Boyle JC, Olssen P, Salvian AJ, **Franciosi LG**, Bain AI (Abstract). Efficacy of Aero-Therapeutic Wound Management (ATM): A Preliminary Study of ATM with Burns - Phase I. (Abstract - Poster) **Second Asian-Pacific Burns Conference**, 8–11 February 1996, Hong Kong, China.
25. Polyakov GM, Boyle JC, Olssen P, Salvian AJ, **Franciosi LG**, Bain AI. Efficacy of Aero-Therapeutic Wound Management (ATM): A Preliminary Study of ATM with Peripheral Vascular Disease - Phase I. (Abstract - Poster) **'Frontiers in Surgery'. The Seventh Wilson TS Wang International Surgical Symposium**, 1–3 December 1995, Hong Kong, China.

## **NON-REFEREED PUBLICATIONS (ABSTRACTS)**

1. **Franciosi LG**, MacLeod BA. Clinical Trial Expert Systems (Abstract - Oral). **Automation and Robotics: The Key For Computer Integrated Health Care Delivery**. Workshop Program by The Peter Wall Institute for Advanced Studies at UBC, 10-12 April 2002, Vancouver, Canada.
2. **Franciosi LG**, Butterfield NN, MacLeod BA. Expert Systems: Certifying Tools for New Therapies (Abstract - Oral). **Symposium on Computer Controlled Drug Therapy**, 13-14 July 2001, Vancouver, Canada.
3. **Franciosi LG**, Butterfield NN, MacLeod BA. Development of a Web-Based Clinical Trial Expert System at UBC (Abstract - Oral). **UBC Faculty of Medicine Golden Jubilee**, 1<sup>st</sup> November 2000, Vancouver, Canada.
4. **Franciosi LG**. Intraspinal NMDA Antagonists (Dextromethorphan) in Mice (Abstract - Oral). **UBC Health Sciences Student Research Forum**, 12<sup>th</sup> October 1993, Vancouver, Canada.
5. **Franciosi LG**, Clinical Evaluation of Intradermal RSD2000 as Peripheral Analgesic in Subjects with Capsaicin-Induced Pain (Abstract - Oral). **UBC Health Sciences Student Research Forum**, 16<sup>th</sup> October 1996, Vancouver, Canada.

## **INVITED PRESENTATIONS**

1. *Markers of Disease & Exacerbation Severity in Chronic Obstructive Pulmonary Disease*. British Pharmacological Society Winter Meeting – Institute of Education Respiratory SIG Symposium Entitled, “*Current and Future Treatment Strategies for Chronic Obstructive Pulmonary Disease*”: Hosts. Dr. Domenico Spina, King’s College London & Dr. Alexandre Trifilileff, Novartis (Symposium Organisers), 21<sup>st</sup> December 2005, London, United Kingdom.
2. *Markers & Modelling of Disease Progression*. Research Seminars at the Pharmaceutical Science Research Division, King’s College London, United Kingdom. Host: Dr. Domenico Spina (Reader in Pharmacology), 12<sup>th</sup> January 2005, London, United Kingdom.
3. *Exacerbations of COPD*. Research Seminar Series at the Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University. Host: Professor Dr. Meindert Danhof (LACDR Director & Head of Division of Pharmacology), 9<sup>th</sup> November 2004, Leiden, The Netherlands.
4. *Markers of Disease Progression in Stable Chronic Obstructive Pulmonary Disease*. Grand Rounds, Department of Pulmonology, Leiden University Medical Center (LUMC). Hosts: Professors. Drs. Klaus Rabe & Peter Sterk (Pulmonologists), 20<sup>th</sup> March 2004, Leiden, The Netherlands.
5. *Review of the Medical Literature for Possible Disease Markers in Stable COPD*. Research Seminar Series at the Leiden/Amsterdam Center for Drug Research (LACDR), Leiden University. Host: Professor Dr. Meindert Danhof (Head of the Division of Pharmacology), 9<sup>th</sup> December 2003, Leiden, The Netherlands.
6. *Disease Progression and Therapeutic Response in Chronic Obstructive Pulmonary Disease (COPD)*. Grand Rounds, Department of Pulmonary, Critical Care & Sleep Medicine, St. Elizabeth’s Medical Center, Tufts University. Host: Professor Bartolome Celli (Pulmonary Specialist), 23<sup>rd</sup> September 2003, Boston, MA, USA.
7. *Good Clinical Practices*. Work in Progress (WiP) Rounds at the Canadian HIV Trials Network & BC Centre for Excellence, St. Paul’s Hospital, Vancouver, BC. Host: Dr. D. Zarowny (Senior Scientific Officer). 20<sup>th</sup> April 1995, Vancouver, BC, Canada.
8. *Aero-Therapeutic Wound Management in Burns and Peripheral Vascular Disease*. Grand Rounds, Department of Vascular and General Surgery, St. Paul’s Hospital, Vancouver, BC. Hosts: Dr. W. Cole (Surgeon-in-Chief), Dr. J. Reid (Vascular Surgeon), and Dr. T. Maxwell (Vascular Surgeon). 23<sup>rd</sup> March 1995, Vancouver, BC, Canada.
9. *Clinical Pharmacology Research Organization (CPRO): Support for Clinical Research*. Grand Rounds: Department of Anesthesia, Vancouver General Hospital - UBC Site. Host: Drs. David Bevan (Head) and B. MacLeod (Practicing Anaesthetist). 21<sup>st</sup> March 1995, Vancouver, Canada.
10. *Aero-Therapeutic Wound Management in Burns and Peripheral Vascular Disease*. Grand Rounds, Department of Plastic Surgery, Vancouver Hospital and Health Sciences Centre, Vancouver, BC; Hosts: Dr. J. Boyle (Director of the Burn Unit & Plastic Surgeon) and Dr. C. Snelling (Head of Research Services & Plastic Surgeon). 8<sup>th</sup> March 1995, Vancouver, Canada.
11. *Aero-Therapeutic Wound Management in Burns and Peripheral Vascular Disease*. Registered Nurses’ Association of BC & BC Children’s Hospital, Vancouver, BC. Host: Ms. Elaine Baxter (RN & Association President). 17<sup>th</sup> October 1995, Vancouver, Canada.
12. *Aero-Therapeutic Wound Management in Burns and Peripheral Vascular Disease*. Canadian Department of National Defense, Ottawa, Ontario; Vancouver Representative & Host: Dr. DRG Brown (Lieutenant-Commander and General Surgeon). 6<sup>th</sup> February 1995, Vancouver, Canada.

## **PERSONAL INTERESTS**

Hiking, sailing, reading newspapers & magazines (e.g., The London Times, The Economist, IEEE Spectrum), watching professional soccer (football) matches (i.e., Manchester United fan), and spending time with family (i.e., wife & 3 kids).

## **REFERENCES**

\*References available upon request